Patents Assigned to Neurelis, Inc.
-
Patent number: 12268664Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: GrantFiled: July 24, 2024Date of Patent: April 8, 2025Assignee: Neurelis, Inc.Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
-
Patent number: 12171868Abstract: Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.Type: GrantFiled: March 24, 2023Date of Patent: December 24, 2024Assignee: Neurelis, Inc.Inventor: Stuart Madden
-
Publication number: 20240374556Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: ApplicationFiled: July 24, 2024Publication date: November 14, 2024Applicant: Neurelis, Inc.Inventors: Steve CARTT, David MEDEIROS, Garry Thomas GWOZDZ, Andrew LOXLEY, Mark MITCHNICK, David F. HALE, Edward T. MAGGIO
-
Publication number: 20240299290Abstract: Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval.Type: ApplicationFiled: January 5, 2024Publication date: September 12, 2024Applicant: Neurelis, Inc.Inventors: Enrique J. CARRAZANA, Adrian L. RABINOWICZ, Sunita MISRA
-
Publication number: 20230399311Abstract: The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof and methods of treatment of neurological conditions including cavernous angioma, cerebral aneurysm, stroke, subarachnoid hemorrhage, vasospasm after subarachnoid hemorrhage, traumatic brain injury, spinal cord injury, spinal cord injury stroke, seizures, hereditary hemorrhagic telangiectasis, cerebral arteriovascular malformations, sporadic cavernous angioma lesion, cerebral cavernous malformation, or combinations thereof, using the same.Type: ApplicationFiled: June 9, 2023Publication date: December 14, 2023Applicants: BioAxone BioSciences, Inc., Neurelis, Inc.Inventors: Kenneth M. ROSEN, Matthew D. ABBINANTI, Lisa MCKERRACHER, Stuart MADDEN
-
Patent number: 11793786Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: GrantFiled: April 12, 2021Date of Patent: October 24, 2023Assignee: Neurelis, Inc.Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
-
Publication number: 20230301903Abstract: Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.Type: ApplicationFiled: March 24, 2023Publication date: September 28, 2023Applicant: Neurelis, Inc.Inventor: Stuart MADDEN
-
Publication number: 20230104144Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: ApplicationFiled: December 6, 2022Publication date: April 6, 2023Applicant: Neurelis, Inc.Inventors: Steve CARTT, David MEDEIROS, Garry Thomas GWOZDZ, Andrew LOXLEY, Mark MITCHNICK, David F. HALE, Edward T. MAGGIO
-
Publication number: 20220401456Abstract: Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.Type: ApplicationFiled: June 10, 2022Publication date: December 22, 2022Applicant: Neurelis, Inc.Inventors: Adrian L. Rabinowicz, Enrique J. Carrazana
-
Publication number: 20220241187Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: ApplicationFiled: April 15, 2022Publication date: August 4, 2022Applicant: Neurelis, Inc.Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David Hale, Edward T. Maggio
-
Publication number: 20220218598Abstract: Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval.Type: ApplicationFiled: January 7, 2022Publication date: July 14, 2022Applicant: Neurelis, Inc.Inventors: Sunita Misra, Enrique J. Carrazana, Adrian L. Rabinowicz, Stuart Madden, Edward T. Maggio
-
Publication number: 20220117887Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: ApplicationFiled: June 2, 2021Publication date: April 21, 2022Applicant: Neurelis, Inc.Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David Hale, Edward T. Maggio
-
Patent number: 11241414Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: GrantFiled: May 27, 2021Date of Patent: February 8, 2022Assignee: Neurelis, Inc.Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
-
Publication number: 20210299089Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: ApplicationFiled: May 27, 2021Publication date: September 30, 2021Applicant: Neurelis, Inc.Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio